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Summary Forty patients with unresectable colorectal metastases confined to the liver were evaluated in a phase 11 study. 5-Fluorouracil
(5-FU) was delivered via a surgically placed hepatic artery catheter. Patients received folinic acid (200 mg m-2) intravenously over 2 h
followed by a loading dose of intra-arterial 5-FU (400 mg m-2) over 15 min, then 5-FU (1600 mg m-2) by intra-arterial infusion over the
following 22 h. This was repeated on day 2 and the whole schedule was repeated every 2 weeks. Response was assessed after six
treatments. The median follow-up was 17 months. Overall response rate was 46% with 8% complete response. Estimated median survival is
19 months. Site of progression was the liver alone in 55%, liver and lung in another 16% and 29% in other sites. Eight patients experienced
grade 3 or 4 toxicity. The response rate of this regimen compares favourably with reported trials of intra-arterial FUDR, and our schedule is
currently being compared with a similar schedule of intravenous 5-FU and folinic acid in a randomized Medical Research Council trial (CR05).
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Colorectal cancer is the second most common cause of cancer
deaths in the UK. Approximately half of the patients undergoing
apparently curative resection will die within 5 years because of
recurrent disease, mostly with liver metastases; in 30% of these
patients the liver will be the only site affected. Few patients are
suitable for surgical treatment, most having multiple metastases
affecting both lobes. Unfortunately, the results of conventional
systemic chemotherapy have been disappointing. For example,
single-agent 5-flourouracil (5-FU) has a response rate of approxi-
mately 10% (Blijham et al, 1996). Furthermore, although the addi-
tion of folinic acid (FA) to 5-FU has resulted in higher response
rates, there remains doubt as to whether this translates into a
survival benefit (Advanced Colorectal Cancer Meta-analysis
Project, 1992).
As most cytotoxic drugs have a steep dose-response curve, it is
a basic pharmacokinetic principle that if one can increase drug
delivery to a tumour then increased response rates can be achieved
(Gamelin et al, 1995). An alternative approach to the therapy of
liver metastases is therefore to deliver the drug intra-arterially. In
the case of patients with liver metastases the arterial route of
delivery is particularly appropriate as ithas been shown that estab-
lished liver metastases over 1 cm in diameter are mainly supplied
by the hepatic artery (Breedis, 1954).
We report our experience of an intra-arterial 5-FU-based
regimen in patients with unresectable colorectal liver metastases.
In this study, we combined three factors that, on the basis of
pharmacological studies, have been shown to offer a therapeutic
advantage, namely intra-arterial administration, infusional rather
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than bolus 5-FU therapy and modulation of 5-FU by high-dose
folinic acid (Kerr et al, 1995). The aim ofthis approach was firstly
to achieve high drug levels within the hepatic metastases and
secondly to deliberately allow the 5-FU to 'spill over' into the
systemic circulation, in an attempt to maximize tumour response
and also delay extrahepatic progression.
PATIENTS AND METHODS
Forty-two patients (17 female, 25 male) with a median age of 60
years (range 33-79 years) with colorectal metastases confined to
the liverand notamenable to surgical resection were included in the
study between July 1993 and March 1996. No patient had adjuvant
chemotherapy for their primary tumour and all had a WHO perfor-
mance score of less than 3. Preoperative assessment included
computerized tomography (CT) scan of the abdomen and pelvis
and either CT scan or radiographic examination of the chest to
exclude extrahepatic disease. Histological confirmation ofthe pres-
ence of liver metastases was obtained by ultrasound-guided needle
biopsy. Selective coeliac and superior mesenteric angiography was
performed before surgery to define hepatic arterial anatomy.
At operation, totally implantable silicone arterial catheters (Jet
Port Plus arterial catheter, Meadox, UK) were inserted. In patients
with normal arterial anatomy, the hepatic artery catheter (HAC) was
inserted retrogradely into the gastroduodenal artery so that the
catheter tip lay at its origin from the common hepatic artery, thereby
gaining access to the hepatic arterial flow. The other end was
connected to a subcutaneous infusion port placed over the costal
margin. To prevent drug-induced cholecystitis, cholecystectomy was
performed routinely. Various surgical manoeuvres were required in
patients with aberrant hepatic arterial anatomy, and these have been
described previously (Anderson et al, 1992). Adequate'perfusion of
the liver was confirmed at the time ofoperation with a test bolus of
Patent Blue dye. Before the patient's discharge, the catheter was
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flushed with heparinized saline (1000 g ml-1) and after a suitable
period ofconvalescence (7-14 days) treatment was started.
The chemotherapy regimen was based on the results ofaprevious
phase I pharmacokinetic study (Kerr et al, 1995). Folinic acid
(200 mg m-2, 10 mg ml-') was infused intravenously over 2 h
followed by an intra-arterial loading dose of 5-FU (400 mg m-2,
25 mg ml-1) over 15 min, then 5-FU (1600 mg m-2, 25 mg ml-', plus
4000 j of heparin per g of 5-FU) by intra-arterial infusion over
22 h. This was repeated on day 2 and the 48-h regimen was repeated
every 2 weeks. The 5-FU intra-arterial infusion was delivered using
an ambulatory pump on an outpatient basis (Howell, 1997) and, on
completion ofthe 2-day regimen, the HAC was flushed with 5 ml of
heparinized saline (1000, ml-'). Ifrequired, before each treatment,
metoclopramide (10 mg, IV) and dexamethasone (8 mg, IV) were
given for antiemesis. Second-line antiemetics and antidiarrhoeals
were given as required. Ranitidine (150 mg b.d.) was prescribed as
prophylaxis against gastroduodenal ulceration. Haematological and
biochemical toxicity were assessed every 2 weeks, along with
systemic toxic effects, and graded according to WHO toxicity
criteria. In patients with significant haematological side-effects, the
subsequent dose was delayed until recovery. In patients with
significant non-haematological side-effects, the subsequent dose was
reduced by 25%.
After six cycles of treatment (3 months), response to therapy was
assessed by CT using standard WHO criteria. Patients who had
responsive or stable disease continued treatment and were reassessed
after every six cycles. Patients who progressed were offered alterna-
tive treatment. Patients whose catheters became occluded orunusable
because of other complications were commenced on an intravenous
De Gramont regimen: FA (200 mgm 2) as a 2-h infusion, 5-FU
(400 mg m-2) bolus, 5-FU (600 mg m-2) infused over 22 h, repeated
on day 2 (De Gramontetal, 1988). Survival analysis (Kaplan-Meier)
was used to predict median survival and times to progression.
RESULTS
Treatment
Ofthe 42patients recruited, 40 received intra-arterial 5-FU. One died
within the immediate post-operative period from bowel ischaemia
and one declined treatment afterhaving a HAC inserted. Onepatient
did notcompleteherfirsttreatment because of5-FUencephalopathy;
she subsequently made a full recovery from this episode but did not
receive further treatment within this trial. She was therefore not eval-
uatedforresponse buthas been included within the survival analysis.
The median number of cycles received was eight (range 1-32).
Median follow-up was 17 months (range 6-31 months).
Response
Response is expressed as best response during the course ofintra-
arterial treatment. Of39 patients who completed theirfirst cycle of
treatment, 18 (46%) responded; of whom, three (8%) had a
complete response and the remainder (38%) a partial response. A
further 11 patients (28%) had stable disease at the time of their
initial assessment.
Toxicity
Three patients had early catheter-related complications. One
patient developed a haematoma and another an abscess at theport
Table 1 Worst systemic toxicity experienced (n= 40)
WHO grade
Symptom 0 1 2 3 4
Nausea and vomiting 23 5 10 2 0
Diarrhoea 26 7 4 1 2
Mucositis 26 5 9 0 0
Haematological (neutropenia
and thrombocytopenia) 26 2 9 3 0
Table 2 Site of first progression (n = 31)
Number of patients (%)
Liver alone 17 (55)
Liver and lung 5 (16)
Lung 2 (6)
Bone 3 (10)
Kidney 1 (3)
Local abdominal/pelvic 3 (10)
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Figure 1 Kaplan-Meier survival curve. Median survival 19 months
site; needle aspiration and antibiotic treatment, respectively,
resolved these problems. One patient had to have the catheter port
resited after gaining weight, and one patient had a leaking catheter
successfully replaced after 12 cycles. Toxicity possibly attribut-
able to perfusion of the upper gastrointestinal (GI) tract was seen
in three patients; this was limited to mild gastritis. The catheter
occluded within the first six cycles of treatment in four (10%)
patients and during the second six cycles in another 12 (31%); in
patients still receiving intra-arterial chemotherapy, the median
time to occlusion was 5 months (range 3-19 months).
Drug-related side-effects were low with only eight patients
experiencing grade 3 or 4 toxicity. Nausea and vomiting were
the most common toxic effects (Table 1). Twenty-five patients
required dose reductions, to 75% of starting dose in 14 patients
and to 50% in 11. One patient experienced 5-FU-related angina;
this responded to dose reduction. In three patients, administration
was delayed for 1 week because ofhaematological toxicity.
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Progression
To date, 31 patients have progressed; the predicted median time to
progression was 17 months. Liver alone was the site of initial
progression in 17 (55%) patients and lung and liver in another five
(16%). In the remaining nine (29%) patients, disease progressed
first at an extrahepatic site (Table 2).
Survival
Of the 40 patients who started treatment, 28 have died, all of
progressive disease. Predicted median survival from the time of
catheter insertion was 19 months (Figure 1).
DISCUSSION
A recent meta-analysis of seven studies (Meta-analysis Group in
Cancer, 1996) comparing intra-arterial (IA) chemotherapy with
either conventional systemic chemotherapy or best supportive care
demonstrated consistently higher response rates in patients
receiving IA chemotherapy. In the UK HAPT study (Allen-Mersh,
1994), patients were randomized to receive intra-arterial fluo-
rouracildeoxyuridine (FUDR) via a totally implantable infusion
device (Infusaid) orbest supportive care; in the lattergroup, 20% of
patients received systemic chemotherapy as palliation. Survival
was significantly longer in the HAC group (median survival 405 vs
226 days). In the French multicentre study (Rougier et al, 1992),
intra-arterial FUDR was compared with systemic intravenous
chemotherapy (weekly bolus 5-FU); however, only 50% ofcontrol
patients received this regimen and the rest received conventional
palliative treatment. The response rate was 43% in the intra-arterial
group compared with 9% in the control group. Furthermore, the IA
group showed a significant increase in survival at 1 (64% vs 44%)
and 2 years (23% vs 13%).
The remaining five studies (Kemeny M et al, 1986; Chang et al,
1987; Kemeny N et al, 1987; Hohn et al, 1989; Martin et al, 1990)
compared intra-arterial therapy with conventional systemic
chemotherapy. Overall, 41% of patients receiving intra-arterial
treatment responded compared with only 14% of those receiving
systemic treatment. The duration of response in both groups was
similar (38 vs 32 weeks respectively). No significant survival
advantage was demonstrated. There were however a number of
flaws in the study designs. All but one of these studies consisted
of very small numbers of patients, two studies used different
chemotherapeutic agents and scheduling in the intra-arterial and
systemic arms. Furthermore, cross-over of patients into the intra-
arterial treatment group upon failure of systemic therapy was
allowed in three studies, thus making a true comparison between
the two routes ofadministration impossible.
In all these studies, FUDR was chosen for the arterial route of
administration. As 84-99% ofthe drug is extracted by the liver on
first pass, it seemed logical to use FUDR to achieve the dual
objective of high levels within the tumour and low plasma levels,
thereby increasing the probability of the tumour's response while
minimizing systemic toxicity. However, although the incidence
of systemic side-effects was low in patients receiving intra-
arterial FUDR, a large number experienced intrahepatic toxicity.
For example, in the French study, chemical hepatitis or biliary
sclerosis occurred in two-thirds ofpatients.
Furthermore, 55% of patients in the above studies developed
extra-hepatic progression, suggesting that these patients may have
had occult extra-hepatic disease at the time of entry into the trial.
The emphasis in the above studies in achieving high drug levels in
liver at the expense of plasma levels may therefore have been
misplaced. As the presence ofextra-hepatic disease clearly limited
survival, it would be important in future studies to ensure that
adequate levels of cytotoxic drug are achieved in the systemic
circulation.
Since the completion of the above studies, several randomized
studies have demonstrated that the addition of folinic acid to
systemically administered 5-FU produces higher response rates
than 5-FU alone (Advanced Colorectal Cancer Meta-analysis
Project, 1992). Therefore, the hypothesis that intra-arterial
treatment is associated with higher response rates and possibly
prolonged survival compared with systemic therapy needs to be
retested.
By infusing 5-FU intra-arterially, which has a lower hepatic
extraction ratio than FUDR, we not only achieved high tumour
drug levels but deliberately allowed the 5-FU to 'spill over' into
the systemic circulation. In this way, we hoped to maximize
response rates within the liver but also to suppress the develop-
ment ofextrahepatic metastases. It seemed likely that both ofthese
objectives could be achieved; our previous pharmacokinetic and
phase I studies showed that high doses of 5-FU could be safely
infused intra-arterially and that this regimen produced equitoxic
and similar steady-state plasma levels compared with conventional
systemic infusional 5-FU (Kerr et al, 1995).
The results were encouraging. The tumour response rate of46%
compares favourably with those of previous studies using intra-
arterial FUDR. Only 29% of patients experienced extra-hepatic
progression as their first sign of relapse, suggesting that thera-
peutic systemic levels were achieved. Systemic toxicity was rela-
tively mild, and in no patient did chemical hepatitis or biliary
sclerosis develop.
Based on the results ofthis study a randomized trial comparing
intra-arterial with systemic 5-FU as treatment for colorectal liver
metastases has been launched by the MRC (Medical Research
Council, 1994). 5-FU is administered by infusion in both limbs,
combined with intravenous FA, and scheduling is similar. Target
recruitment is approximately 350 patients, and this study has been
designed to allow the question of whether intra-arterial therapy
offers asignificant survival advantage compared with conventional
systemic chemotherapy to be answered.
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